Flibanserin is a drug originally
developed by Boehringer-Ingelheim and later Sprout Pharmaceuticals, which was approved in 2015 by the FDA for the
treatment of premenopausal women with hypoactive sexual
desire disorder (HSDD). The drug, which was originally
developed for the treatment of depression by Boehringer-
Ingelheim, is a full agonist of the 5-HT1A receptor, an
antagonist of the 5-HT2A receptor, and a partial agonist of
the dopamine-4 (D4) receptor, which triggers increased
dopamine and norepinephrine levels along with decreased
serotonin levels. In three randomized trials
involving 2400 premenopausal women, the drug was found
to increase the number of satisfying sexual events by 0.5-1.0
events per month and increased sexual desire on average by
10-12% over placebo. Side effects include decreased blood
pressure and loss of consciousness, especially in subjects who
consumed alcohol.
??
Antidepressant (5-HT1a agonist and 5-HT2 antagonist).
